1
|
Maguire S, Kesby A, Brownlow R, Hunt GE, Kim M, McAulay C, Grisham JR, McGregor IS, Suraev A, Kevin RC, Russell J. A phase II randomised controlled trial of intranasal oxytocin in anorexia nervosa. Psychoneuroendocrinology 2024; 164:107032. [PMID: 38520886 DOI: 10.1016/j.psyneuen.2024.107032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 02/13/2024] [Accepted: 03/17/2024] [Indexed: 03/25/2024]
Abstract
BACKGROUND Anorexia nervosa (AN) is an eating disorder (ED) with high mortality rates and limited response to existing treatments, prompting the need to identify effective agents and adjuncts. There is evidence for an emerging role for the neuropeptide oxytocin (OT) in the pathophysiology of AN, with studies showing a perturbed oxytocinergic system in patients with AN. Preliminary evidence has demonstrated that intranasal OT (IN-OT) can produce anxiolytic effects in AN, as well as reducing concern about eating, and dysfunctional attentional biases related to the disorder. IN-OT is a non-invasive treatment option for AN that requires investigation as an adjunct to nutritional rehabilitation. METHODS This multi-site study (Trial Registration:ACTRN1261000897460) sought to replicate and extend a previous randomised placebo-controlled pilot trial of repeated dose IN-OT in patients with AN hospitalised for nutritional rehabilitation. Patients with AN (N=61) received daily IN-OT (18 IU twice per day) or placebo for four weeks, whilst undergoing inpatient hospital treatment. Outcome measures included ED psychopathology (primary) as measured by the Eating Disorder Examination (EDE) and Body Mass Index (BMI; secondary). Participants were assessed pre- and post-treatment, and at six months following the intervention. The effects of the first and last doses of IN-OT on responses (anxiety ratings and salivary cortisol) to a high-energy snack were also examined. RESULTS Sixty-one female inpatients (Mage=24.36,SD=7.87) with an average BMI of 16.24 (range: 11.43-18.55), were recruited into the study. No significant differences were found between placebo and OT groups at any of the time points on the outcomes of interest, but significant improvements in almost all psychological parameters in both groups were evident over time. IN-OT did not significantly reduce anxiety nor salivary cortisol in response to a high-calorie snack. CONCLUSION This is the largest randomised placebo-controlled trial of repeated dose intranasal OT in people with AN, during refeeding. The therapeutically promising findings of the pilot study were not replicated. Limitations and reasons for the non-replication included relatively large variance, baseline psychopathology scores being higher in this patient group, potential ceiling effects in BMI and ED psychopathology as well as differing comorbidities.
Collapse
Affiliation(s)
- Sarah Maguire
- Inside Out Institute, Charles Perkins Building, University of Sydney, NSW 2006, Australia; Sydney Local Health District, Missenden Rd, Camperdown, NSW 2050, Australia; Faculty of Medicine & Health, University of Sydney, NSW 2006, Australia.
| | - Alice Kesby
- Faculty of Science, School of Psychology, University of Sydney, NSW 2006, Australia.
| | - Rachel Brownlow
- Faculty of Science, School of Psychology, University of Sydney, NSW 2006, Australia
| | - Glenn E Hunt
- Sydney Local Health District, Missenden Rd, Camperdown, NSW 2050, Australia; Discipline of Psychiatry, University of Sydney, Sydney, NSW 2006, Australia
| | - Marcellinus Kim
- Sydney Local Health District, Missenden Rd, Camperdown, NSW 2050, Australia; Professor Marie Bashir Centre, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
| | - Claire McAulay
- Faculty of Science, School of Psychology, University of Sydney, NSW 2006, Australia
| | - Jessica R Grisham
- UNSW Sydney, Faculty of Science, School of Psychology, Anzac Parade, Randwick, NSW 2031, Australia
| | - Iain S McGregor
- Faculty of Science, School of Psychology, University of Sydney, NSW 2006, Australia; University of Sydney, Brain and Mind Centre, Mallet St, Camperdown, NSW 2050, Australia; University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Brain Mind Centre, Mallet St, Camperdown, NSW 2050, Australia
| | - Anastasia Suraev
- Faculty of Science, School of Psychology, University of Sydney, NSW 2006, Australia; University of Sydney, Brain and Mind Centre, Mallet St, Camperdown, NSW 2050, Australia; University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Brain Mind Centre, Mallet St, Camperdown, NSW 2050, Australia
| | - Richard C Kevin
- Faculty of Medicine & Health, University of Sydney, NSW 2006, Australia; University of Sydney, Brain and Mind Centre, Mallet St, Camperdown, NSW 2050, Australia; University of Sydney, Lambert Initiative for Cannabinoid Therapeutics, Brain Mind Centre, Mallet St, Camperdown, NSW 2050, Australia
| | - Janice Russell
- Inside Out Institute, Charles Perkins Building, University of Sydney, NSW 2006, Australia; Sydney Local Health District, Missenden Rd, Camperdown, NSW 2050, Australia; Faculty of Medicine & Health, University of Sydney, NSW 2006, Australia; Discipline of Psychiatry, University of Sydney, Sydney, NSW 2006, Australia; Professor Marie Bashir Centre, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050, Australia
| |
Collapse
|
2
|
Bryson C, Douglas D, Schmidt U. Established and emerging treatments for eating disorders. Trends Mol Med 2024; 30:392-402. [PMID: 38503683 DOI: 10.1016/j.molmed.2024.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2024] [Revised: 02/21/2024] [Accepted: 02/22/2024] [Indexed: 03/21/2024]
Abstract
Eating disorders (EDs) are common mental health conditions that carry exceedingly high morbidity and mortality rates. Evidence-based treatment options include a range of psychotherapies and some, mainly adjunctive, pharmacological interventions. However, around 20-30% of people fail to respond to the best available treatments and develop a persistent treatment-refractory illness. Novel treatments for these disorders are emerging, but their efficacy and clinical relevance need further investigation. In this review article, we first outline the evidence-base for the established treatments of the three 'classical' EDs [anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)]. We then review research on some of the most promising emerging treatment modalities, discussing the questions and challenges that remain.
Collapse
Affiliation(s)
- Callum Bryson
- Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK
| | - Daire Douglas
- Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK
| | - Ulrike Schmidt
- Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.
| |
Collapse
|
3
|
Guo W, Xiong W. From gut microbiota to brain: implications on binge eating disorders. Gut Microbes 2024; 16:2357177. [PMID: 38781112 PMCID: PMC11123470 DOI: 10.1080/19490976.2024.2357177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2023] [Accepted: 05/15/2024] [Indexed: 05/25/2024] Open
Abstract
The prevalence of eating disorders has been increasing over the last 50 years. Binge eating disorder (BED) and bulimia nervosa (BN) are two typical disabling, costly and life-threatening eating disorders that substantially compromise the physical well-being of individuals while undermining their psychological functioning. The distressing and recurrent episodes of binge eating are commonly observed in both BED and BN; however, they diverge as BN often involves the adoption of inappropriate compensatory behaviors aimed at averting weight gain. Normal eating behavior is coordinated by a well-regulated trade-off between intestinal and central ingestive mechanism. Conversely, despite the fact that the etiology of BED and BN remains incompletely resolved, emerging evidence corroborates the notion that dysbiosis of gastrointestinal microbiome and its metabolites, alteration of gut-brain axis, as well as malfunctioning central circuitry regulating motivation, execution and reward all contribute to the pathology of binge eating. In this review, we aim to outline the current state of knowledge pertaining to the potential mechanisms through which each component of the gut-brain axis participates in binge eating behaviors, and provide insight for the development of microbiome-based therapeutic interventions that hold promise in ameliorating patients afflicted with binge eating disorders.
Collapse
Affiliation(s)
- Weiwei Guo
- Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Research Center for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei, China
| | - Wei Xiong
- Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Hefei National Research Center for Physical Sciences at the Microscale, University of Science and Technology of China, Hefei, China
- Anhui Province Key Laboratory of Biomedical Imaging and Intelligent Processing, Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei, China
- CAS Key Laboratory of Brain Function and Disease, Hefei, China
| |
Collapse
|
4
|
Sysko R, Holland K, Hildebrandt T. Adapting dose-response methodology to improve clinical trial design for psychotherapies. Int J Eat Disord 2023. [PMID: 38135456 DOI: 10.1002/eat.24120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 12/11/2023] [Accepted: 12/11/2023] [Indexed: 12/24/2023]
Abstract
OBJECTIVE Conventional randomized controlled trials (RCTs) have long served as the foundation of research in clinical psychology; however, most treatments for eating disorders show only modest effects on reduction of symptoms and maintenance of long-term remission. New options for psychotherapy treatment development research, beyond continuing to pursue additive or subpopulation approaches, are needed. METHODS One option is to apply dose-response designs, which are commonplace in studies of pharmacology, toxicology, and medical research, and characterized by the evaluation of the amount of exposure (dose) to an intervention, and the resulting changes in body function or health (response). RESULTS Eating disorder interventions are particularly well-suited for dose-response treatment designs. The deadly nature of eating disorders makes it imperative that patients are not turned away for not being "ready" to engage with treatment. By identifying optimal doses, research will likely yield a more parsimonious course of treatment, which will lend itself to reduced costs, greater uptake, and reduced drop-out. DISCUSSION Limited use of within-subject designs in trials for patients with eating disorders has produced fast-track efficacy studies and omitted key elements in the treatment development pathway. To decrease reliance on RCT's, dose-response methods should be applied as an alternative study design. PUBLIC SIGNIFICANCE Eating disorders are associated with medical and psychiatric comorbidities, poor quality of life, and high mortality. Access to evidence-based services for patients with eating disorders is limited, and identifying additional effective treatment options can be difficult because of challenges inherent to randomized-controlled trials. This manuscript describes an alternative trial methodology to maximize the information that can be gathered prior to utilizing a standard large-scale efficacy design.
Collapse
Affiliation(s)
- Robyn Sysko
- Department of Psychiatry, Center of Excellence in Eating and Weight Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Katherine Holland
- Department of Psychiatry, Center of Excellence in Eating and Weight Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Tom Hildebrandt
- Department of Psychiatry, Center of Excellence in Eating and Weight Disorders, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|